RecruitingNot ApplicableNCT03144167

Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy

Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

170 participants

Start Date

Jun 18, 2019

Study Type

INTERVENTIONAL

Conditions

Chemotherapy Radiotherapy Glioblastoma

Summary

No predictive factors are known for the response to the bevacizumab anti-angiogenic molecule (Avastin) given in the event of relapse of glioblastoma (GBM) following radiochemotherapy. Classical MRI with gadolinium injection and perfusion is not sufficient to predict survival and response or duration. We propose to evaluate the prognostic interest for 6-month survival of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism recorded at 7 and 28 days of application of the treatment. These biomarkers are based on the increase of an index combining choline / Creatine (Cho / Cr), Glx / Cr (Glutamine and glutamate / Creatine), NAA / Cr (N acetyl aspartate / Creatine) and lactate / Cr ratios. The long-term objective is to predict the survival of these relapsed GBM patients at an early stage and to identify responder patients who would benefit from this expensive molecule and avoid using it in non-responding patients

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for biological markers in the blood that can predict whether patients with glioblastoma (an aggressive brain tumor) that has come back after standard treatment will survive at least 6 months when treated with bevacizumab (a drug that cuts off the tumor's blood supply). **You may be eligible if...** - You are between 18 and 88 years old - You have a confirmed diagnosis of glioblastoma that has come back for the first time after surgery, radiation, and temozolomide chemotherapy - Your blood counts and organ function are within acceptable ranges - You have health insurance and are willing to sign a consent form **You may NOT be eligible if...** - Your glioblastoma is coming back for the second time or more - Your blood counts or organ function (liver, kidneys) are below the required levels - You have significant protein in your urine Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAnalysis of spectroscopic biomarkers of proliferation for six-month survival

Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival